BACKGROUND: The National Surgical Quality Improvement Program (NSQIP) is a risk-adjusted database designed to benchmark quality initiatives. NSQIP captures uniform morbidity variables for all operations and calculates expected morbidity probabilities. Given the frequent need for reoperation following breast-conserving surgery (BCS) and mastectomy, we hypothesized that NSQIP may inaccurately reflect surgical morbidity after breast cancer operations. METHODS: Using the 2008 NSQIP database, we identified 24,447 breast surgery patients. We calculated the observed versus expected (O/E) morbidity ratios, compared them to other general surgery procedures, and analyzed the O/E morbidity ratios among benign and malignant breast diagnoses. RESULTS: The NSQIP database shows that breast surgery has an O/E morbidity ratio of 3.11, which is higher than other general surgery procedures. Additionally, breast operations for malignancy have higher O/E morbidity ratios (3.22) than those performed for benign disease (2.59). Analysis of malignant patients by CPT code revealed that BCS patients had an O/E morbidity ratio of 7.75 and attributed 89 % of morbidity to reoperation, whereas mastectomy patients had an O/E morbidity ratio of only 1.7. Elimination of the reoperation variable from morbidity calculations in breast surgery reduces the O/E morbidity ratio to less than expected in all breast procedures. DISCUSSION: Breast surgery has a higher O/E morbidity ratio than other general surgery procedures. Reoperations are expected in BCS for positive margins and in mastectomy for completion ALND. Breast surgeons should advocate for benchmarking by surgical site-specific metrics, because current NSQIP criteria may negatively affect the quality assessment of high-volume breast centers.
BACKGROUND: The National Surgical Quality Improvement Program (NSQIP) is a risk-adjusted database designed to benchmark quality initiatives. NSQIP captures uniform morbidity variables for all operations and calculates expected morbidity probabilities. Given the frequent need for reoperation following breast-conserving surgery (BCS) and mastectomy, we hypothesized that NSQIP may inaccurately reflect surgical morbidity after breast cancer operations. METHODS: Using the 2008 NSQIP database, we identified 24,447 breast surgery patients. We calculated the observed versus expected (O/E) morbidity ratios, compared them to other general surgery procedures, and analyzed the O/E morbidity ratios among benign and malignant breast diagnoses. RESULTS: The NSQIP database shows that breast surgery has an O/E morbidity ratio of 3.11, which is higher than other general surgery procedures. Additionally, breast operations for malignancy have higher O/E morbidity ratios (3.22) than those performed for benign disease (2.59). Analysis of malignant patients by CPT code revealed that BCS patients had an O/E morbidity ratio of 7.75 and attributed 89 % of morbidity to reoperation, whereas mastectomy patients had an O/E morbidity ratio of only 1.7. Elimination of the reoperation variable from morbidity calculations in breast surgery reduces the O/E morbidity ratio to less than expected in all breast procedures. DISCUSSION: Breast surgery has a higher O/E morbidity ratio than other general surgery procedures. Reoperations are expected in BCS for positive margins and in mastectomy for completion ALND. Breast surgeons should advocate for benchmarking by surgical site-specific metrics, because current NSQIP criteria may negatively affect the quality assessment of high-volume breast centers.
Authors: S E Tevis; H B Neuman; E A Mittendorf; H M Kuerer; I Bedrosian; S M DeSnyder; A M Thompson; D M Black; M E Scoggins; A A Sahin; K K Hunt; A S Caudle Journal: Ann Surg Oncol Date: 2018-06-26 Impact factor: 5.344
Authors: Janak Atul Parikh; Joal D Beane; E Molly Kilbane; Daniel P Milgrom; Henry A Pitt Journal: J Am Coll Surg Date: 2014-09-03 Impact factor: 6.113
Authors: Parhom Towfighi; Romina Deldar; Zoe K Haffner; Nathan Aminpour; Olutayo Sogunro; Areeg A Abu El Hawa; Marc Boisvert; Kenneth L Fan Journal: Breast Cancer Res Treat Date: 2022-05-27 Impact factor: 4.872
Authors: Anna Palubicka; Radoslaw Jaworski; Marcin Wekwejt; Beata Swieczko-Zurek; Michal Pikula; Janusz Jaskiewicz; Jacek Zielinski Journal: Medicina (Kaunas) Date: 2019-08-21 Impact factor: 2.430
Authors: Jacquelyn Dillon; Samantha M Thomas; Laura H Rosenberger; Gayle DiLalla; Oluwadamilola M Fayanju; Carolyn S Menendez; E Shelley Hwang; Jennifer K Plichta Journal: Ann Surg Oncol Date: 2021-07-26 Impact factor: 4.339